These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16675572)

  • 21. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue.
    Yan PS; Venkataramu C; Ibrahim A; Liu JC; Shen RZ; Diaz NM; Centeno B; Weber F; Leu YW; Shapiro CL; Eng C; Yeatman TJ; Huang TH
    Clin Cancer Res; 2006 Nov; 12(22):6626-36. PubMed ID: 17121881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methylation of serum DNA is an independent prognostic marker in colorectal cancer.
    Wallner M; Herbst A; Behrens A; Crispin A; Stieber P; Göke B; Lamerz R; Kolligs FT
    Clin Cancer Res; 2006 Dec; 12(24):7347-52. PubMed ID: 17189406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer.
    Yu J; Cheng YY; Tao Q; Cheung KF; Lam CN; Geng H; Tian LW; Wong YP; Tong JH; Ying JM; Jin H; To KF; Chan FK; Sung JJ
    Gastroenterology; 2009 Feb; 136(2):640-51.e1. PubMed ID: 19084528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
    Koensgen D; Mustea A; Klaman I; Sun P; Zafrakas M; Lichtenegger W; Denkert C; Dahl E; Sehouli J
    Gynecol Oncol; 2007 Nov; 107(2):266-73. PubMed ID: 17698176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
    Hartmann O; Spyratos F; Harbeck N; Dietrich D; Fassbender A; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Lerebours F; Welzel K; Maier S; Plum A; Niemann S; Foekens JA; Lesche R; Martens JW
    Clin Cancer Res; 2009 Jan; 15(1):315-23. PubMed ID: 19118060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of gene expression in early-stage ovarian cancer.
    Marchini S; Mariani P; Chiorino G; Marrazzo E; Bonomi R; Fruscio R; Clivio L; Garbi A; Torri V; Cinquini M; Dell'Anna T; Apolone G; Broggini M; D'Incalci M
    Clin Cancer Res; 2008 Dec; 14(23):7850-60. PubMed ID: 19047114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
    Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
    Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.
    Cottrell S; Jung K; Kristiansen G; Eltze E; Semjonow A; Ittmann M; Hartmann A; Stamey T; Haefliger C; Weiss G
    J Urol; 2007 May; 177(5):1753-8. PubMed ID: 17437806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles.
    Bauerschlag DO; Ammerpohl O; Bräutigam K; Schem C; Lin Q; Weigel MT; Hilpert F; Arnold N; Maass N; Meinhold-Heerlein I; Wagner W
    Oncology; 2011; 80(1-2):12-20. PubMed ID: 21577013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer.
    Kikuchi R; Tsuda H; Kozaki K; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
    Cancer Res; 2008 Jul; 68(13):5067-75. PubMed ID: 18593905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy.
    Zheng Y; Katsaros D; Shan SJ; de la Longrais IR; Porpiglia M; Scorilas A; Kim NW; Wolfert RL; Simon I; Li L; Feng Z; Diamandis EP
    Clin Cancer Res; 2007 Dec; 13(23):6984-92. PubMed ID: 18056174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
    Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
    Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer.
    Hoque MO; Feng Q; Toure P; Dem A; Critchlow CW; Hawes SE; Wood T; Jeronimo C; Rosenbaum E; Stern J; Yu M; Trink B; Kiviat NB; Sidransky D
    J Clin Oncol; 2006 Sep; 24(26):4262-9. PubMed ID: 16908936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Promoter hypermethylation identifies progression risk in bladder cancer.
    Yates DR; Rehman I; Abbod MF; Meuth M; Cross SS; Linkens DA; Hamdy FC; Catto JW
    Clin Cancer Res; 2007 Apr; 13(7):2046-53. PubMed ID: 17404085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
    Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients.
    Gyorffy B; Lánczky A; Szállási Z
    Endocr Relat Cancer; 2012 Apr; 19(2):197-208. PubMed ID: 22277193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene-expression profiling in epithelial ovarian cancer.
    Konstantinopoulos PA; Spentzos D; Cannistra SA
    Nat Clin Pract Oncol; 2008 Oct; 5(10):577-87. PubMed ID: 18648354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of gene expression profiles to stage concurrent endometrioid tumors of the endometrium and ovary.
    Guirguis A; Elishaev E; Oh SH; Tseng GC; Zorn K; DeLoia JA
    Gynecol Oncol; 2008 Feb; 108(2):370-6. PubMed ID: 18083218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.